DIASORIN SPA (DIA.MI) Stock Price, Forecast & Analysis
Europe • Euronext Milan • BIT:DIA • IT0003492391
DIA.MI Key Statistics, Chart & Performance
The current stock price of DIA.MI is 74.54 EUR. In the past month the price decreased by -0.43%. In the past year, price decreased by -26.01%.
DIA.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DIA.MI. When comparing the yearly performance of all stocks, DIA.MI is a bad performer in the overall market: 67.75% of all stocks are doing better.
DIA.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to DIA.MI. DIA.MI scores excellent on profitability, but there are some minor concerns on its financial health.
DIA.MI Financial Highlights
Over the last trailing twelve months DIA.MI reported a non-GAAP Earnings per Share(EPS) of 3.31. The EPS decreased by -5.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.87% | ||
| ROA | 6.56% | ||
| ROE | 12.26% | ||
| Debt/Equity | 0.35 |
DIA.MI Forecast & Estimates
18 analysts have analysed DIA.MI and the average price target is 83.19 EUR. This implies a price increase of 11.6% is expected in the next year compared to the current price of 74.54.
For the next year, analysts expect an EPS growth of 5.04% and a revenue growth 0.83% for DIA.MI
DIA.MI Ownership
DIA.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 16.58 | 109.689B | ||
| SHL | SIEMENS HEALTHINEERS AG | 17.22 | 46.022B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 18.12 | 23.755B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 18.12 | 23.746B | ||
| BIM | BIOMERIEUX | 18.85 | 11.049B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 19 | 3.843B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 11.95 | 2.495B | ||
| DRW3 | DRAEGERWERK AG - PREF | 12.16 | 1.636B | ||
| DRW8 | DRAEGERWERK AG | 9.7 | 1.317B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About DIA.MI
Company Profile
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
Company Info
DIASORIN SPA
Via Crescentino Snc
Saluggia VERCELLI IT
Employees: 3279
Phone: 3901614871
DIASORIN SPA / DIA.MI FAQ
What does DIASORIN SPA do?
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
What is the current price of DIA stock?
The current stock price of DIA.MI is 74.54 EUR. The price decreased by -0.05% in the last trading session.
Does DIASORIN SPA pay dividends?
DIASORIN SPA (DIA.MI) has a dividend yield of 1.61%. The yearly dividend amount is currently 1.14.
What is the ChartMill technical and fundamental rating of DIA stock?
DIA.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is DIA.MI stock listed?
DIA.MI stock is listed on the Euronext Milan exchange.
Is DIASORIN SPA (DIA.MI) expected to grow?
The Revenue of DIASORIN SPA (DIA.MI) is expected to grow by 0.83% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for DIASORIN SPA?
DIASORIN SPA (DIA.MI) has a market capitalization of 4.17B EUR. This makes DIA.MI a Mid Cap stock.